Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 26.50 GBp
Change Today -0.50 / -1.85%
Volume 88.5K
VAL On Other Exchanges
As of 11:30 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

valirx plc (VAL) Snapshot

27.00 GBp
Previous Close
27.00 GBp
Day High
27.00 GBp
Day Low
26.50 GBp
52 Week High
05/27/15 - 76.75 GBp
52 Week Low
09/18/15 - 20.50 GBp
Market Cap
Average Volume 10 Days
-0.11 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VALIRX PLC (VAL)

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx plc, a biopharmaceutical company, develops novel technologies and products in oncology therapeutics and diagnostics in the United Kingdom and rest of Europe. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of genes by targeted histone deacetylation that leads to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials used for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; and VAL401, the reformulation of a generic drug, which is in pre-clinical stage for the treatment of lung cancer and other oncology indications. Its drug candidates also comprise VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. In addition, the company engages in the development of NAV3, a cancer screening test, which is in Phase I clinical trials for the detection of cancer cells in tissue samples. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

12 Employees
Last Reported Date: 04/23/15
Founded in 2000

valirx plc (VAL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 150.0K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 54.1K GBP
Chief Operating Officer and Director
Total Annual Compensation: 88.0K GBP
Compensation as of Fiscal Year 2014.

valirx plc (VAL) Key Developments

Valirx Plc Reports Unaudited Consolidated Earnings Results for the Half Year Ended June 30, 2015

ValiRx Plc reported unaudited consolidated earnings results for the half year ended June 30, 2015. For the half year, the company reported revenue of £153,099 compared to £59,574 a year ago. Operating loss was £1,563,154 compared to £1,139,028 last year. Loss before taxation was £1,372,501 compared to £1,493,032 last year. Loss and total comprehensive income attributable to owners of the parent was £1,336,944 or 4.80 pence per basic and diluted share compared to £1,748,480 or 5.71 pence per basic and diluted share last year. Cash outflows from operating activities were £1,368,561 compared to £1,701,701 last year. Payments to acquire intangible assets were £172,010 compared to £162,881 last year.

ValiRx plc Provides VAL201 Clinical Trial Update

ValiRx plc provided a further update on its lead compound, VAL201, in its Phase l/ll dose escalation clinical trial, which is approved to include patients with locally advanced or metastatic prostate cancer and other advanced solid tumours. Over the past month, the approved incremental dose escalation has continued to demonstrate safety and tolerability, with no significant adverse effects recorded. In addition, the compound continues to show similar properties and results in terms of delaying disease progression in patients with locally advanced or metastatic prostate cancer to those witnessed in pre-clinical studies. In light of the additional safety and tolerability data that has been obtained, the next dose escalation has been approved, which may prove sufficient to show anti-tumour activity. This would continue a trend that, thus far, has been seen throughout the clinical trial. The trial is on track and is proceeding according to timetable. As the trial proceeds, further updates and information will be provided.

ValiRx plc Provides an Update on VAL201, in Its Phase l/ll Dose Escalation Clinical Trial

ValiRx Plc provided an update on its lead compound, VAL201, in its Phase l/ll dose escalation clinical trial. The trial has been approved to include patients with locally advanced or metastatic prostate cancer and other advanced solid tumours at University College London Hospital. The trial to date has successfully demonstrated safety and tolerability and there have been no significant adverse effects. There are preliminary indications that the compound VAL201 is demonstrating the effects that have been seen in the preclinical studies. The trial is now advancing through the planned dose escalation, where further safety and tolerability testing is being undertaken and efficacy will be further investigated. Where increased dosing has been undertaken, no significant adverse effects have occurred. Further subjects have been identified and recruited according to the criteria laid out in the trial protocol. The trial is on track and proceeding according to the timetable and plan. Future updates will be provided as the trial progresses.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 26.50 GBp -0.50

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies

Industry Analysis


Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.1x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 57.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at